Is micropapillary serous carcinoma for real?

Authors

  • David M. Gershenson M.D.

    Corresponding author
    1. Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Department of Gynecologic Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 440, Houston, TX 77030
    Search for more papers by this author
    • Fax: (713) 745-3510


  • See accompanying editorial on pages 675–6 and referenced original article on pages 791–800, this issue.

Abstract

Approximately 3000 American women are diagnosed with borderline ovarian tumors annually. The most common histologic type of borderline ovarian tumor is the serous type. The article by Bristow et al. focuses on two of the major clinical controversies regarding serous borderline tumors: the significance and classification of the micropapillary pattern and the optimal treatment of recurrence, specifically the role of secondary cytoreductive surgery.

See also pages 675–6 and 791–800.

Ancillary